AcSDKP: A new potential marker of malignancy of the thyroid gland

Langenbeck's Archives of Surgery

Volumn 391, Issue 1, 2006, Pages 9-12

  Kusinski, Michal ^a,c   Wdzieczak Bakala, Joanna ^b   Liu, Jian Miao ^b   Bignon, Jerome ^b   Kuzdak, Krzysztof ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

^b CNRS   (France)

^c Klinika Chirurgii Endokrynologicznej I Ogolnej UM W Lodzi   (Poland)

Author keywords

AcSDKP; Angiogenesis; Papillary cancer; Thyroid

Indexed keywords

SERASPENIDE;

ADULT; AGED; ARTICLE; BENIGN TUMOR; COMPARATIVE STUDY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DISEASE MARKER; DISEASE SEVERITY; ENZYME IMMUNOASSAY; FEMALE; HUMAN; HUMAN TISSUE; INTRAOPERATIVE PERIOD; MALE; NODULAR GOITER; PRIORITY JOURNAL; THYROID CANCER; THYROID GLAND; THYROID PAPILLARY CARCINOMA; TISSUE LEVEL;

ADULT; AGED; CARCINOMA, PAPILLARY; FEMALE; HUMANS; MALE; MIDDLE AGED; OLIGOPEPTIDES; THYROID NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 31944451540     PISSN: 14352443     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00423-005-0014-4     Document Type: Article

References (24)

1. Folkman J (1971) Tumor angiogenesis: therapeutic implications. N Engl J Med 285(21):1182-1186
2. Kołomecki K, Bartos M, Pomorski L, Kuzdak K (2001) The influence of thyroidectomy of serum VEGF levels in patients with Graves disease. Wiad Lek 54(9-10):504-507
3. Ramsden JD (2000) Angiogenesis in the thyroid gland. J Endocrinol 166 (3):475-480
4. Stȩpién HM, Kolomecki K, Pasieka Z, Komorowski J, Stȩpién T, Kuzdak K (2002) Angiogenesis of endocrine gland tumours - new molecular targets in diagnostics and therapy. Eur J Endocrinol 146(2):143-151
5. Lin SY, Wang YY, Sheu WH (2003) Preoperative plasma concentrations of vascular endothelial growth factor and matrix metalloproteinase 9 are associated with stage progression in papillary thyroid cancer. Clin Endocrinol (Oxf) 58(4):513-518
6. Lantsov D, Meirmanov S, Nakashima M, Kondo H, Saenko V, Naruke Y, Namba H, Ito M, Abrosimov A, Lushnikov E, Sekine I, Yamashita SH (2005) Cyclin D1 overexpression in thyroid papillary microcarcinoma: its association with tumour size and aberrant beta-catenin expression. Histopathology 47(3):248-256
7. Karger S, Berger K, Eszlinger M, Tannapfel A, Dralle H, Paschke R, Fuhrer D (2005) Evaluation of peroxisome proliferator-activated receptor-gamma expression in benign and malignant thyroid pathologies. Thyroid 15(9):997-1003
8. Kehlen A, Englert N, Seifert A, Klonisch T, Dralle H, Langner J, Hoang-Vu C (2004) Expression, regulation and function of autotaxin in thyroid carcinomas. Int J Cancer 109(6):833-838
9. Kebebew E, Peng M, Reiff E, Duh QY, Clark OH, McMillan A (2005) ECM1 and TMPRSS4 are diagnostic markers of malignant thyroid neoplasms and improve the accuracy of fine needle aspiration biopsy. Ann Surg 242 (3):353-361
10. 4 and endoproteinase Asp-N in the biosynthesis of the tetrapeptide AcSerAspLysPro a regulator of the hematopoietic system. FEBS Lett 274 (1-2):30-34
11. Lenfant M, Wdzieczak-Bakala J, Guittet E, Prome JC, Sotty D, Frindel E (1989) Inhibitor of hematopoietic pluripotent stem cell proliferation: purification and determination of its structure. Proc Natl Acad Sci U S A 86(3):779-782
12. Bonnet D, Lemoine FM, Pontvert-Delucq S, Baillou C, Najman A, Guigon M (1993) Direct and reversible inhibitory effect of the tetrapeptide acetyl-N-Ser-Asp-Lys-Pro (Seraspenide) on the growth of human CD34+ subpopulations in response to growth factors. Blood 82(11):3307-3314
13. Liu JM, Lawrence F, Kovacevic M, Bignon J, Papadimitriou E, Lallemand JY, Katsoris P, Potier P, Fromes Y, Wdzieczak-Bakala J (2003) The tetrapeptide AcSDKP, an inhibitor of primitive hematopoietic cell proliferation, induces angiogenesis in vitro and in vivo. Blood 101(8):3014-3020
14. Fromes Y, Liu JM, Kovacevic M, Bignon J, Wdzieczak-Bakala J (2005) The tetrapeptide AcSDKP improves skin flap survival and accelerates wound healing. Wound Repair Regen (submitted for publication)
15. Yang F, Yang XP, Liu YH, Xu J, Cingolani O, Rhaleb NE, Carretero OA (2004) AcSDKP reverse inflammation and fibrosis in rats with heart failure after myocardial infarction. Hypertension 43(2):229-236
16. Liozon E, Pradelles P, Venot J, Rigaud M, Cransac M, Bordessoule D, Frindel E (1993) Serum levels of a negative regulator of cell proliferation (AcSDKP) are increased in certain human haemopathies. Leukemia 7 (6):808-812
17. 4 in mouse tissues. FEBS Lett 289(2):171-175
18. 4 from a human medullary thyroid carcinoma. J Endocrinol 118(1):155-159
19. Hall AK (1991) Differential expression of thymosin genes in human tumors and in the developing human kidney. Int J Cancer 48(5):672-677
20. 10 gene overexpression correlated with the highly malignant neoplastic phenotype of transformed thyroid cells in vivo and in vitro. Cancer Res 58(4):823-828
21. Chiappetta G, Pentimalli F, Monaco M, Fedele M, Pasquinelli R, Pierantoni GM, Ribecco MT, Santelli G, Califano D, Pezzullo L, Fusco A (2004) Thymosin beta-10 gene expression as a possible tool in diagnosis of thyroid neoplasias. Oncol Rep 2(2):239-243
22. 4 in tumor metastasis and angiogenesis. J Natl Cancer Inst 95(22):1674-1680
23. Chen C, Li M, Yang H, Chai H, Fisher W, Yao Q (2005) Roles of thymosins in cancers and other organ systems. World J Surg 29(3):264-270
24. 10 inhibits angiogenesis and tumor growth by interfering with Ras function. Cancer Res 65(1):137-148